Kowa Pharmaceutical Europe (kpe) Co. Ltd

WOKINGHAM, England, July 18, 2011 - - Study Demonstrated no Significant Impact on Blood Levels When LIVAZO (pitavastatin) was Taken With HIV Protease Inhibitor Combination lopinavir/ritonavir in Healthy Volunteers Kowa Pharmaceuticals America, Inc.

WOKINGHAM, England, June 27, 2011 - Today, at the European Atherosclerosis Society (EAS) congress, Kowa Pharmaceutical Europe announced results from a post marketing surveillance study showing pitavastatin provides consistent long-term increases in high-density lipoprotein cholesterol (HDL-C) in a broad range of patients with hypercholesterolaemia.[1] The data from the Livalo Effectiveness and Safety (LIVES) Study Extension showed a relationship between on-treatment serum HDL-C levels and cardiovascular risk, and that pitavastatin consistently provided clinically relevant elevations in HDL-C that continued to increase over five years.